Clinical Trial Update: A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing Tobemstomig plus nab-paclitaxel versus pembrolizumab plus nab-paclitaxel in previously untreated PD-L1-positive locally-advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)
• Tobemstomig

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING